AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.
Shares were up 8% during intraday trading.
Here's a closer look at four of venture capital funds' favorite publicly traded names in 2017.
Venture capital funds added shares of these four publicly traded stocks to their portfolios last quarter. Should you?